This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc (TDOC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 34.48% and 1.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring Analyst Estimates for Teladoc (TDOC) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Teladoc (TDOC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Teladoc (TDOC) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw Teladoc (TDOC) settling at $8.60, representing a -0.92% change from its previous close.
Strength Seen in MultiPlan (MPLN): Can Its 9.0% Jump Turn into More Strength?
by Zacks Equity Research
MultiPlan (MPLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Teladoc (TDOC) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Teladoc (TDOC) reachead $8.41 at the closing of the latest trading day, reflecting a -0.71% change compared to its last close.
Teladoc Stock Rises 12% as Jefferies Boosts Price Target on BetterHelp
by Zacks Equity Research
TDOC's stock benefits from improving web traffic in its BetterHelp platform.
Why Teladoc (TDOC) Outpaced the Stock Market Today
by Zacks Equity Research
Teladoc (TDOC) closed at $8.16 in the latest trading session, marking a +0.87% move from the prior day.
Why Teladoc (TDOC) Outpaced the Stock Market Today
by Zacks Equity Research
Teladoc (TDOC) closed at $7.25 in the latest trading session, marking a +0.83% move from the prior day.
Teladoc Stock Near 52-Week Low: Is it Healthy Enough to Invest?
by Zacks Equity Research
TDOC is well positioned to grow in the long run on the back of expanding product offerings, memberships, AI integration, business diversification and global expansions.
Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?
by Debanjana Dey
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Here's Why Teladoc (TDOC) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, Teladoc (TDOC) stood at $7.17, denoting a +0.99% change from the preceding trading day.
Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity
by Zacks Equity Research
The latest FDA clearance of Masimo's (MASI) W1 medical watch is likely to provide a continuous and accurate view of patients' health data.
Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?
by Debanjana Dey
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.
Teladoc (TDOC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc (TDOC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 22.22% and 1.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Teladoc (TDOC) Q2 Earnings Navigate BetterHelp Profit Woes?
by Zacks Equity Research
Teladoc's (TDOC) second-quarter results are likely to reflect lower advertising and marketing expenses.
Countdown to Teladoc (TDOC) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Teladoc (TDOC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $9.30, moving +1.2% from the previous trading session.
Teladoc (TDOC) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $9.39, moving +0.21% from the previous trading session.
Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?
by Debanjana Dey
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Teladoc (TDOC) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Teladoc (TDOC) closed at $10.14 in the latest trading session, marking a -0.1% move from the prior day.
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%
by Zacks Equity Research
AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.
Teladoc (TDOC) Soars 6.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) concluded the recent trading session at $10.11, signifying a +1.1% move from its prior day's close.